Molecular subtyping with PAM50 based intrinsic breast cancer subtype test Prosigna® for Early Breast Cancer (EBC) above and beyond clinical standard

Prosigna® - gene expression breast cancer subtyping assay and its transition to the nCounter platform (Philip Bernard, Huntsman Cancer Institute, USA)

Chemotherapy–“yes” or “no” and what do we learn about late recurrence by molecular characterization (Michael Gnant, Medical University of Vienna, Austria)

Influence of Prosigna®-Breast Cancer Intrinsic Subtype Test (BCIST) on treatment decisions in EBC (Nadia Harbeck, University of Munich, Germany)

Webcasts will be available from each presentation after the satellite symposium